Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancerChemoimmunotherapy Shows Higher Response Rates in Bladder Cancer

Frontiers in Medicine Published June 13, 2026 DOI ↗ Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that neoadjuvant chemoimmunotherapy yields higher pCR rates than chemotherapy alone but involves higher toxicity.

This network meta-analysis evaluates the comparative efficacy and safety of neoadjuvant chemoimmunotherapy (NICT), chemotherapy alone (NAC), and immunotherapy alone (IT) in patients with muscle-invasive bladder cancer. The analysis included 2234 patients to compare pathological complete response (pCR) rates across three treatment modalities.

The findings indicate that NICT is superior to NAC for achieving pCR, with an OR of 4.2 (95% CI: 2.0-8.2). Specifically, the pCR rates were 0.41 for NICT (95% CI: 0.37-0.46), 0.26 for IT (95% CI: 0.17-0.39), and 0.15 for NAC (95% CI: 0.10-0.23).

Regarding safety, NICT was associated with higher toxicity than IT, though no statistically significant pairwise differences were found between NAC, NICT, and IT regarding grade $≥$3 treatment-related adverse events. A noted limitation of the evidence is the lack of long-term survival outcomes, such as overall survival or recurrence-free survival.

Clinically, NICT demonstrates the best efficacy for pCR but carries a higher toxicity profile than IT. Conversely, IT offers a safer profile while maintaining meaningful efficacy compared to NAC.

How this fits prior evidence

This finding addresses a gap in comparing specific neoadjuvant regimens for muscle-invasive bladder cancer. While previous coverage has explored immunotherapy and chemotherapy combinations in other cancers like advanced endometrial cancer and breast cancer, this study specifically quantifies the pCR advantage of NICT over NAC (OR 4.2) and IT in the context of bladder cancer.

Researchers analyzed data from 2,234 patients with muscle-invasive bladder cancer (MIBC) to compare three different treatment paths. They looked at neoadjuvant chemoimmunotherapy (NICT), chemotherapy alone (NAC), and immunotherapy alone (IT). The primary goal was to see which method resulted in the highest pathological complete response (pCR) rate.

The results showed that NICT had the highest pCR rate at 0.41, followed by IT at 0.26, and then NAC at 0.15. While NICT appeared more effective at achieving this specific goal, it was also associated with higher toxicity than immunotherapy alone. There were no statistically significant differences found between the three treatments regarding severe side effects.

Because this study focused on response rates rather than long-term survival or recurrence, the results are not yet definitive for long-term outcomes. Patients and doctors should consider that while NICT shows better efficacy in these figures, it comes with more toxicity. Talk to a doctor to weigh these options based on individual health needs.

What this means for you:

Chemoimmunotherapy showed higher response rates than other methods but also involved higher levels of toxicity.

Common questions

How effective is chemoimmunotherapy for bladder cancer?

The study found that neoadjuvant chemoimmunotherapy (NICT) had the highest pathological complete response rate at 0.41. This was higher than immunotherapy alone (0.26) and chemotherapy alone (0.15). However, these results only measure immediate response rates and do not provide data on long-term survival or recurrence.

Are there side effects with these treatments?

NICT was associated with higher toxicity than immunotherapy alone. While the study did not find statistically significant differences in severe grade 3 or higher adverse events between all three treatment types, it is important to discuss specific risks and your personal health profile with a medical professional.

How does chemoimmunotherapy compare to chemotherapy alone?

The analysis showed that NICT had a significantly higher odds ratio of 4.2 compared to chemotherapy alone for achieving a complete response. While it may be more effective at reaching this specific goal, the study notes that it also comes with higher toxicity levels than some other options.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedJun 2026

View Original Abstract ↓

IntroductionMuscle-invasive bladder cancer (MIBC) carries a poor prognosis, and the optimal neoadjuvant treatment strategy remains debated. This study aimed to systematically compare the efficacy and safety of neoadjuvant chemoimmunotherapy (NICT), chemotherapy alone (NAC), and immunotherapy alone (IT) for MIBC.MethodsA Bayesian network meta-analysis was conducted. We systematically searched PubMed, Embase, Cochrane Library, and Web of Science for relevant randomized controlled trials and prospective/retrospective cohort studies published up to June 2025. The primary outcomes were pathological complete response (pCR) rate and the incidence of grade ≥3 treatment-related adverse events (TRAEs). Data analysis was performed using R software with appropriate packages for network meta-analysis.ResultsFourteen studies involving 2234 patients were included. The pooled pCR rate was highest for NICT (0.41, 95% CI: 0.37-0.46), followed by IT (0.26, 95% CI: 0.17-0.39) and NAC (0.15, 95% CI: 0.10-0.23). Network meta-analysis showed NICT was significantly superior to NAC for pCR (OR = 4.2, 95% CI: 2.0-8.2). For grade ≥3 TRAEs, the pooled incidence was highest for NAC (0.19, 95% CI: 0.07-0.39), followed by NICT (0.12, 95% CI: 0.09-0.18) and IT (0.06, 95% CI: 0.04-0.10), with no statistically significant pairwise differences. Ranking probabilities indicated NICT had the highest likelihood of being the most efficacious treatment but also the highest probability of adverse events.ConclusionNICT demonstrates the best efficacy in the neoadjuvant treatment of MIBC but is associated with relatively higher toxicity, making it suitable for patients with good cisplatin tolerance. However, the analysis is limited by the lack of long-term survival outcomes such as overall survival and recurrence-free survival. IT offers a safer profile with meaningful efficacy and represents a viable option for patients with poor toxicity tolerance. Treatment selection should be individualized based on efficacy-safety trade-offs and patient-specific factors.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251171346, identifier CRD420251171346.

Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancerChemoimmunotherapy Shows Higher Response Rates in Bladder Cancer

How this fits prior evidence

Common questions

Study Details

Transbronchial biopsy with 1.1-mm cryoprobe yields 88.6% diagnosis versus 78.8% with 2.0-mm forceps

Cryoprobe biopsy shows higher success rate for diagnosing lung conditions

Clinical research that matters. Delivered to your inbox.

Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancerChemoimmunotherapy Shows Higher Response Rates in Bladder Cancer

How this fits prior evidence

Common questions

More on Muscle-Invasive Bladder Cancer

Study Details

Transbronchial biopsy with 1.1-mm cryoprobe yields 88.6% diagnosis versus 78.8% with 2.0-mm forceps

Cryoprobe biopsy shows higher success rate for diagnosing lung conditions

Clinical research that matters. Delivered to your inbox.

Related in Oncology

From Other Specialties